Количественное определение глиофибриллярного кислого белка (GFAP) в сыворотке крови больных глиомами мозга методом твердофазного иммуноферментного анализа с использованием моноклональных aнти-GFAP-антител

Полученные результаты в сочетании с данными иммуногистохимических исследований позволяют считать экспрессию антигена GFAP достаточно стабильной для использования его в качестве мишени для направленного транспорта препаратов в клетки глиомы.

Quantification of gfap in serum of patients with brain gliomas by means of elysa emploing monoclonal anti-GFAP-antibodies

51 patients with brain gliomas were studied. 26 patients aged 10-63 years, had high grade gliomas. 25 patients aged 4-57 years, had low grade gliomas. Quantification of GFAP in serum was performed by ELYSA employing monoclonal anti-GFAP-antibodies. The aim of the research was to evaluate expression of GFAP by different types of glioma. 100% patients showed an increased GFAP level. High grade gliomas group showed the highest GFAP con- centration in blood (32-256 ng/ml). GFAP concentrations in blood of patients with low grade gliomas were 16-128 ng/ml. We found a mild correlation between GFAP concentration in blood and size of high grade gliomas. The data obtained indicated that GFAP expression by glioma cells was quite stable. It is confirmed by immunohistochemical studies of GFAP pres- ence in glial tumor tissues. So we can conclude that GFAP may be used for target delivery of\ antineoplastic drugs to glioma cells.